It’s a promising new drug for multiple myeloma, one of the most savage blood cancers. Called Ninlaro, it can be taken as a pill, sparing patients painful injections or cumbersome IV treatments. In a video sponsored by the manufacturer, Takeda Pharmaceutical Co., one patient even hailed Ninlaro as “my savior.” The U.S. Food and Drug Administration approved it in 2015 after patients in a clinical trial gained an average of six months without their cancer spreading. That trial, though, had a major shortcoming: its racial composition. One out of five people diagnosed with multiple myeloma in the U.S. is...Read More
Byline: Caroline Chen and Riley Wong - ProPublica
Sparing the Rod and
Saving Our Children
Stacey Patton pro-vides a powerful, heart-breaking look at the link with white supremacy and why it's time to stop hitting our children, for their sake and the future of black families. Click here to read.